MRK Meets Primary Endpoint
Merk's Phase 3 ATLAS-UC study of Tulisokibart meets primary endpoint of clinical remission in patients with moderately to severely active UC
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.